A phase I study of MGCD 0103 given as a three-times weekly oral dose in patients with advanced solid tumours or non-Hodgkin's lymphoma
Phase of Trial: Phase I
Latest Information Update: 09 Jan 2015
At a glance
- Drugs Mocetinostat (Primary)
- Indications Non-Hodgkin's lymphoma; Solid tumours
- Focus Adverse reactions
- Sponsors Celgene Corporation; MethylGene; Pharmion Corporation
- 12 May 2009 Additional lead trial investigator Martell R identified as reported by ClinicalTrials.gov.
- 11 Dec 2008 Actual completion date reported as October 2008 by ClinicalTrials.gov.
- 11 Dec 2008 Status changed from suspended to completed as reported by ClinicalTrials.gov.